Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. VALBIOTIS
  6. News
  7. Summary
    ALVAL   FR0013254851

VALBIOTIS

(ALVAL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Valbiotis : Reportd Positive Preclinical Results Of Hypertension Drug

04/12/2021 | 05:40am EDT


ę MT Newswires 2021
All news about VALBIOTIS
06/07VALBIOTISá : Appointment of Sébastien BESSY as Chief Operating Marketing and Bus..
PU
06/03VALBIOTISá : Publication of the first scientific papers on TOTUM•63 in thre..
PU
05/26VALBIOTISá : granted a Ç 1.25 million innovation support loan by Bpifrance
PU
05/20GLOBAL MARKETS LIVE : Ford, Intel, Cisco, EasyJet, Oatly...
05/12VALBIOTISá : rsquo; Combined General Meeting on May 27, 2021 will exceptionally ..
PU
05/12VALBIOTISá : AGM 2021 – Special Auditors' report – Res. 15 (in Frenc..
PU
04/15VALBIOTISá : Investors presentation – April 2021
PU
04/12VALBIOTISá : Reportd Positive Preclinical Results Of Hypertension Drug
MT
03/22VALBIOTISá : obtains ISO 9001 certification for its activities in “Design,..
PU
03/22VALBIOTISá : Obtains ISO 9001 Certification for Its Activities in "Design, Devel..
BU
More news
Financials
Sales 2021 2,43 M 2,90 M 2,90 M
Net income 2021 -8,77 M -10,5 M -10,5 M
Net cash 2021 9,83 M 11,7 M 11,7 M
P/E ratio 2021 -6,20x
Yield 2021 -
Capitalization 66,4 M 79,3 M 79,2 M
EV / Sales 2021 23,2x
EV / Sales 2022 7,21x
Nbr of Employees 35
Free-Float 84,9%
Chart VALBIOTIS
Duration : Period :
VALBIOTIS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALBIOTIS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,85 €
Average target price 13,67 €
Spread / Average Target 99,5%
EPS Revisions
Managers and Directors
NameTitle
Sebastien M. Peltier Chairman & Chief Executive Officer
Jocelyn Pineau Chief Financial & Administrative Officer
Laurent LÚvy Chairman-Supervisory Board
Pascal Sirvent Chief Scientific Officer
SÚbastien Bessy Director-Operations, Marketing & Sales
Sector and Competitors
1st jan.Capitalization (M$)
VALBIOTIS13.04%79
GILEAD SCIENCES, INC.14.40%84 093
WUXI APPTEC CO., LTD.36.51%68 536
BIONTECH SE181.53%57 117
REGENERON PHARMACEUTICALS9.66%55 301
VERTEX PHARMACEUTICALS-20.66%48 892